Allergan Selects ImageIQ as Imaging CRO for LiRIS® Interstitial Cystitis Clinical Trial

CLEVELAND, Ohio--ImageIQ, an innovative Imaging Software and Contract Research Organization focused on supporting preclinical research and clinical trials, announced today that it has been chosen by Allergan, to provide its full complement of clinical research imaging support services and technology for a new clinical trial. ImageIQ's technology and services will be utilized in support of Allergan's safety and efficacy study of their LiRIS® product in females presenting with interstitial cystitis with Hunner's Lesions. Specifically, Allergan will leverage ImageIQ's EDCIQ™ imaging-enabled electronic data capture (EDC) system, customized specifically to the study's design and workflow to support compliance with all imaging-related activities. Additionally, ImageIQ will develop and validate the imaging and image analysis protocols, provide study site imaging qualification, training and management, and provide quantitative software-based image analysis and data management.

About ImageIQ

ImageIQ is an Imaging Contract Research Organization (ICRO) providing image management software, image analysis capabilities and professional services for imaging in drug and device clinical trials, We combine software engineering with biomedical and imaging expertise to provide quantitative, visual analysis and operational efficiency. Our mission is to enhance R&D and product efficacy/safety testing for research, medical device, and pharmaceutical organizations. By advancing the speed of research, ImageIQ clients can extend their expertise and abilities and complete work quickly, allowing innovative staff members to focus on creative solutions to research. www.Image-IQ.com or @ImageIQ via Twitter

About Allergan

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 10,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.

Contacts

ImageIQ, Inc.
Brett Hoover, VP Sales and Marketing
855-462-4347
[email protected]
http://www.image-iq.com

 

Suggested Articles

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.